Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sensei Biotherapeutics ( (SNSE) ) has provided an announcement.
On October 17, 2025, Sensei Biotherapeutics announced promising results from their Phase 1/2 trial of solnerstotug, a monoclonal antibody targeting VISTA, presented at the ESMO Congress 2025. The trial showed a 6-month progression-free survival rate of 50% in the 15 mg/kg dose cohort for PD-(L)1 resistant tumors, surpassing historical benchmarks. The treatment demonstrated a favorable safety profile, with only mild cytokine release syndrome observed. These results support the advancement to Phase 2 studies, which are planned for 2026, focusing on Non-Small Cell Lung Cancer and Merkel Cell Carcinoma, potentially leading to accelerated approval for PD-1 resistant populations.
The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.
Spark’s Take on SNSE Stock
According to Spark, TipRanks’ AI Analyst, SNSE is a Underperform.
Sensei Biotherapeutics faces substantial financial challenges, with no revenue and ongoing net losses. The technical analysis indicates a bearish trend, and the valuation is poor due to negative earnings. However, the positive corporate event regarding trial results offers a glimpse of potential future success. The overall score reflects these mixed factors, with financial weaknesses being the most significant deterrent.
To see Spark’s full report on SNSE stock, click here.
More about Sensei Biotherapeutics
Sensei Biotherapeutics is a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer patients. Utilizing its TMAb™ platform, the company creates conditionally active therapeutics that target the tumor microenvironment to either disable immunosuppressive signals or activate immunostimulatory signals, aiming to enhance T cell activity against tumors. Their lead product candidate, solnerstotug, is designed to selectively block the VISTA checkpoint within the tumor microenvironment.
Average Trading Volume: 19,301
Technical Sentiment Signal: Buy
Current Market Cap: $22.17M
For an in-depth examination of SNSE stock, go to TipRanks’ Overview page.